Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00869336 · ClinicalTrials.gov registry record · Phase 2
Multicenter Study of the Efficacy and Safety of Luliconazole Cream in Tinea Pedis (Athlete's Foot)
A Phase 2 study, sponsored by Tinea Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 147
- Enrollment target
NCT00869336: Completed Phase 2 study, sponsored by Tinea Pharmaceuticals.
NCT00869336 is a Phase 2 study that has completed, run by Tinea Pharmaceuticals. The registered enrollment target is 147 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (11% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00869336, a Phase 2 study, has completed, sponsored by Tinea Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 147 participants
- Enrollment target
Study Summary
To examine the safety and optimal duration of Luliconazole Cream 1% treatments for 14 days or 28 days to achieve "complete clearance" at 2 weeks post treatment.
Interventions
- DRUG Luliconazole Cream 1% - 2 wks
- DRUG Placebo Comparator -2 wks
- DRUG Luliconazole Cream 1% - 4 wks
- DRUG Placebo Comparator - 4 wks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2009-03 |
| Est. Completion | 2009-09 |
| Phase | Phase 2 |
What the finished NCT00869336 record still lists
NCT00869336 is an interventional study that assigns participants to a tested intervention. The registered 147 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (11% higher).
The record links to 0 conditions, and to 4 interventions - of which Luliconazole Cream 1% - 2 wks is the first listed.
NCT00869336 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00869336 about?
NCT00869336 is a clinical study titled "Multicenter Study of the Efficacy and Safety of Luliconazole Cream in Tinea Pedis (Athlete's Foot)". To examine the safety and optimal duration of Luliconazole Cream 1% treatments for 14 days or 28 days to achieve "complete clearance" at 2 weeks post treatment.
What is the current status of trial NCT00869336?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 147 participants. The study started on 2009-03. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00869336?
The interventions under investigation include: Luliconazole Cream 1% - 2 wks (DRUG), Placebo Comparator -2 wks (DRUG), Luliconazole Cream 1% - 4 wks (DRUG), Placebo Comparator - 4 wks (DRUG).
Who is sponsoring clinical trial NCT00869336?
This trial is sponsored by Tinea Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00869336's enrollment target sits among peer trials
147 495th of 2000 higher than 1,505 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04396613 · 147 participants · NA
Wound Closure Techniques in Primary Spine Surgery
- NCT04851119 · 147 participants · Phase 1
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- NCT05523947 · 147 participants · Phase 1
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
- NCT06121843 · 147 participants · Phase 1
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia